|

Lupus Clinical Trials in New York, NY

34 recruiting studies within 50 miles

Phase
Trial Phase Dist.
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPhase 1<1 mi
Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)—<1 mi
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune DiseasesPhase 2<1 mi
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune DiseasePhase 1<1 mi
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLEPhase 1/2<1 mi
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus ErythematosusPhase 1<1 mi
IMPACT Study: IMProve Pregnancy in APS With Certolizumab TherapyPhase 2<1 mi
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune DiseasePhase 1<1 mi
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) StudyPhase 2<1 mi
Alnuctamab for Refractory SLE (LATTE Study)Phase 1<1 mi
Effects of Stopping Hydroxychloroquine in Elderly Lupus DiseasePhase 3<1 mi
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric ParticipantsPhase 3<1 mi
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)—<1 mi
A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132Phase 4<1 mi
Lupus Landmark Study: A Prospective Registry and Biorepository—<1 mi
Safety of the Herpes Zoster Subunit Vaccine in LupusPhase 4<1 mi
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus ErythematosusPhase 1/2<1 mi
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)Phase 1/2<1 mi
Safety and Efficacy of ONT01 in LupusEarly 1<1 mi
VIBRANT: VIB4920 for Active Lupus NephritisPhase 2<1 mi
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus ErythematosusPhase 3<1 mi
Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)Phase 2<1 mi
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyPhase 2<1 mi
HEALTH Home Urinalysis TestingN/A<1 mi
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants—5 mi
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus ErythematosusPhase 39 mi
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric ParticipantsPhase 29 mi
Transforming Care for Individuals With Childhood-onset Systemic Lupus ErythematosusN/A12 mi
A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus NephritisPhase 217 mi
Trial of Belimumab in Early LupusPhase 417 mi
Transcutaneous Vagus Nerve Stimulation in SLEPhase 217 mi
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus ErythematosusPhase 329 mi
PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus NephritisPhase 429 mi
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- VPhase 250 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.